ArticleLipids in health and disease2025
CRP-triglyceride-glucose index (CTGI) as a predictor of preeclampsia: a population-based study of risk stratification.
Article in Lipids in health and disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundpreeclampsia (PE) remains a leading cause of maternal and perinatal morbidity and mortality worldwide. While metabolic and inflammatory factors are increasingly recognized in its pathogenesis, the clinical utility of composite biomarkers remains underexplored. This study aimed to investigate the association between the C-reactive protein-triglyceride-glucose (CRP-TG-glucose) index (CTGI), a novel marker of metabolic-inflammation stress, and the risk of preeclampsia.
methodsThis retrospective cohort study included 11,916 pregnant women, of whom 486 developed preeclampsia. Maternal baseline characteristics were compared between the PE and non-PE groups. Logistic regression analyses were conducted to identify factors associated with PE. The relationship between CTGI and PE risk was further explored using quartile stratification, restricted cubic spline regression, and threshold effect analyses. Subgroup analyses were also performed to assess interaction effects across maternal and obstetric variables.
resultsWomen with PE had significantly higher maternal age, body mass index (BMI), in vitro fertilization (IVF) conception, multifetal pregnancies, and elevated CTGI levels compared to non-PE counterparts (all P < .001). Multivariate logistic regression identified CTGI as an independent risk factor for PE (adjusted OR, 1.78; 95% CI, 1.51-2.09; P < .001), alongside BMI, maternal age, IVF, and multifetal gestation. A dose-response relationship was observed across CTGI quartiles, with the highest quartile showing a markedly increased PE risk (adjusted OR, 2.06; 95% CI, 1.52-2.81). Restricted cubic spline models and threshold analysis revealed a nonlinear association with a significant inflection point at CTGI = 2.244. Above this threshold, the risk of PE rose sharply (OR, 3.93; 95% CI, 2.09-7.39; P < .001). Subgroup analyses demonstrated consistent associations across maternal age, BMI, parity, plurality, and IVF status, without significant interaction.
conclusionsElevated CTGI in early pregnancy is independently and nonlinearly associated with an increased risk of preeclampsia, particularly above a critical threshold of 2.244. These findings underscore the potential clinical value of CTGI as an early risk stratification biomarker for PE, enabling timely intervention in high-risk pregnancies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.